As the most basic physiological process, breathing and the whole respiratory tract involved in this act are closely related to human health. In recent years, studies on airway microecology imbalance during COPD and bronchiectasis have revealed, that the characteristics of lower airway microecology are closely related to progression of respiratory diseases and provided new insights on medical treatment options, and therefore caused rising of new ideas about clinical intervention into microecology imbalance to stop disease progression. Regarding asthma, the research and development of new drugs for the upstream inflammatory pathway became a leading direction in the treatment for asthma patients, including patients with non-type 2 increased airway inflammation. Bronchial thermoplasty, bronchoscopy, lung volume reduction, targeted denervation and other technologies have made great progress in the treatment of COPD and asthma. However, in the field of acute hypoxic respiratory failure treatment, the existing clinical trials results revealed, that clear therapeutic targets leading to reduction of the mortality of patients have not been discovered yet, and it requires to put more efforts to explore the effectiveness of other treatment approaches.

Proswell Medical Development Center Respiratory Disease team always happy to assist clients with research and development of new respiratory drugs. Respiratory Disease team leader has many years of respiratory clinical work experience in diagnostic and treatment of respiratory diseases like refractory asthma, chronic obstructive pulmonary disease, pulmonary infectious disease, pulmonary vascular disease, interstitial pulmonary disease, and ability to organically combine the clinical diagnosis and treatment experience and skills with the design and implementation of clinical trials. Our team has participated in different projects including pulmonary embolism, new coronavirus pneumonia treatment, chronic obstructive pulmonary disease, and other respiratory diseases. In terms of therapeutics diverse administration methods experience, our team successfully conducted trials for drugs administered orally, by inhalation, by injection and as a spray. We have built good cooperation and relationship with many well-known respiratory system drugs developing companies and reputed industry experts in China and around the globe.

Our respiratory dedicated medical team provides one stop medical service for all indications and all trial phases for the new investigational drug, including but not limited to: CDP development, medical writing, Health Authority communication, protocol development, medical monitoring, and CSR development.